ASBP
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-98.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ASBP vs ATAI
Revenue, margins, valuation, and 5-year total return — side by side.
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.+158.7%
ASBP vs ATAI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBP | ATAI |
|---|---|---|
| Industry | Biotechnology | Medical - Pharmaceuticals |
| Market Cap | $7M | $964M |
| Revenue (TTM) | $2K | $3M |
| Net Income (TTM) | $-32M | $-154M |
| Gross Margin | 45.5% | -259.1% |
| Operating Margin | -10314.4% | -34.6% |
| Total Debt | $1M | $25M |
| Cash & Equiv. | $4K | $18M |
ASBP vs ATAI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBP
ATAI
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 1.2 | -98.8% |
| Atai Beckley N.V (ATAI) | 100 | 258.7 | +158.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBP vs ATAI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATAI leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ASBP
Aspire Biopharma Holdings, Inc.
The Specific-Use Pick
In this particular matchup, ASBP is outpaced on most metrics by others in the set.
Best for: healthcare exposure
ATAI
Atai Beckley N.V
The Income Pick
ATAI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.48
- Rev growth -1.9%, EPS growth -272.0%, 3Y rev CAGR -75.3%
- -47.7% 10Y total return vs ASBP's -98.7%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs ASBP's -13.7% |
| Quality / Margins | ATAI | -51.1% margin vs ASBP's -16K% |
| Stability / Safety | ATAI | Beta 1.48 vs ASBP's 1.74 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATAI | +188.5% vs ASBP's -52.6% |
| Efficiency (ROA) | ATAI | -64.3% ROA vs ASBP's -13.2% |
ASBP vs ATAI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
ASBP vs ATAI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATAILAGGINGASBP
ASBPAspire Biopharma Hold…
1leads
ATAIAtai Beckley N.V
4leads
6 Total Categories
CATEGORYLEADERvs ASBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATAI3/4
Valuation MetricsMultiples, price ratios, and targets
ATAI1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ASBP3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
ATAI5/6
Risk & VolatilityBeta, volatility, and downside exposure
ATAI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATAI leads this category, winning 3 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATAI is the larger business by revenue, generating $3M annually — 1554.9x ASBP's $1,941. ATAI is the more profitable business, keeping -51.1% of every revenue dollar as net income compared to ASBP's -16352.0%.
| Metric | ASBPAspire Biopharma … | ATAIAtai Beckley N.V |
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $3M |
| EBITDAEarnings before interest/tax | -$28M | -$103M |
| Net IncomeAfter-tax profit | -$32M | -$154M |
| Free Cash FlowCash after capex | -$4M | -$90M |
| Gross MarginGross profit ÷ Revenue | +45.5% | -2.6% |
| Operating MarginEBIT ÷ Revenue | -10314.4% | -34.6% |
| Net MarginNet income ÷ Revenue | -16352.0% | -51.1% |
| FCF MarginFCF ÷ Revenue | -1811.5% | -29.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.7% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -75.0% |
ATAI leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
ATAI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ASBPAspire Biopharma … | ATAIAtai Beckley N.V |
|---|---|---|
| Market CapShares × price | $7M | $964M |
| Enterprise ValueMkt cap + debt − cash | $9M | $971M |
| Trailing P/EPrice ÷ TTM EPS | -0.60x | -4.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3130.37x |
| Price / BookPrice ÷ Book value/share | — | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
ATAI leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ASBP leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
| Metric | ASBPAspire Biopharma … | ATAIAtai Beckley N.V |
|---|---|---|
| ROE (TTM)Return on equity | — | -96.4% |
| ROA (TTM)Return on assets | -13.2% | -64.3% |
| ROICReturn on invested capital | — | -45.0% |
| ROCEReturn on capital employed | — | -50.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | — | 0.21x |
| Net DebtTotal debt minus cash | $1M | $7M |
| Cash & Equiv.Liquid assets | $3,633 | $18M |
| Total DebtShort + long-term debt | $1M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | -68.93x |
ASBP leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
ATAI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATAI five years ago would be worth $2,016 today (with dividends reinvested), compared to $135 for ASBP. Over the past 12 months, ATAI leads with a +188.5% total return vs ASBP's -52.6%. The 3-year compound annual growth rate (CAGR) favors ATAI at 25.9% vs ASBP's -76.2% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | ATAIAtai Beckley N.V |
|---|---|---|
| YTD ReturnYear-to-date | +13.1% | +3.6% |
| 1-Year ReturnPast 12 months | -52.6% | +188.5% |
| 3-Year ReturnCumulative with dividends | -98.7% | +99.5% |
| 5-Year ReturnCumulative with dividends | -98.7% | -79.8% |
| 10-Year ReturnCumulative with dividends | -98.7% | -47.7% |
| CAGR (3Y)Annualised 3-year return | -76.2% | +25.9% |
ATAI leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ATAI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATAI is the less volatile stock with a 1.48 beta — it tends to amplify market swings less than ASBP's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATAI currently trades 59.4% from its 52-week high vs ASBP's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | ATAIAtai Beckley N.V |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 1.48x |
| 52-Week HighHighest price in past year | $2.45 | $6.75 |
| 52-Week LowLowest price in past year | $0.05 | $1.29 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +59.4% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 51.5 |
| Avg Volume (50D)Average daily shares traded | 15.0M | 6.0M |
ATAI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ASBPAspire Biopharma … | ATAIAtai Beckley N.V |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $12.00 |
| # AnalystsCovering analysts | — | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATAI leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). ASBP leads in 1 (Profitability & Efficiency).
Best OverallAtai Beckley N.V (ATAI)Leads 4 of 6 categories
Loading custom metrics...
ASBP vs ATAI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ASBP or ATAI a better buy right now?
Analysts rate Atai Beckley N.
V (ATAI) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASBP or ATAI?
Over the past 5 years, Atai Beckley N.
V (ATAI) delivered a total return of -79. 8%, compared to -98. 7% for Aspire Biopharma Holdings, Inc. (ASBP). Over 10 years, the gap is even starker: ATAI returned -47. 7% versus ASBP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASBP or ATAI?
By beta (market sensitivity over 5 years), Atai Beckley N.
V (ATAI) is the lower-risk stock at 1. 48β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 18% more volatile than ATAI relative to the S&P 500.
04Which has better profit margins — ASBP or ATAI?
Atai Beckley N.
V (ATAI) is the more profitable company, earning -484. 6% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps -484. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATAI leads at -333. 4% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ASBP or ATAI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ASBP or ATAI better for a retirement portfolio?
For long-horizon retirement investors, Atai Beckley N.
V (ATAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATAI: -47. 7%, ASBP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ASBP and ATAI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.